ATE479774T1 - Durch rna-interferenz vermittelte hemmung der genexpression unter verwendung von sina (short interfering nucleic acid) - Google Patents
Durch rna-interferenz vermittelte hemmung der genexpression unter verwendung von sina (short interfering nucleic acid)Info
- Publication number
- ATE479774T1 ATE479774T1 AT03743684T AT03743684T ATE479774T1 AT E479774 T1 ATE479774 T1 AT E479774T1 AT 03743684 T AT03743684 T AT 03743684T AT 03743684 T AT03743684 T AT 03743684T AT E479774 T1 ATE479774 T1 AT E479774T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleic acid
- gene expression
- rna
- short interfering
- sina
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35858002P | 2002-02-20 | 2002-02-20 | |
US36312402P | 2002-03-11 | 2002-03-11 | |
US38678202P | 2002-06-06 | 2002-06-06 | |
US40678402P | 2002-08-29 | 2002-08-29 | |
US40837802P | 2002-09-05 | 2002-09-05 | |
US40929302P | 2002-09-09 | 2002-09-09 | |
US44012903P | 2003-01-15 | 2003-01-15 | |
PCT/US2003/005028 WO2003074654A2 (en) | 2002-02-20 | 2003-02-20 | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE479774T1 true ATE479774T1 (de) | 2010-09-15 |
Family
ID=43446817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03743684T ATE479774T1 (de) | 2002-02-20 | 2003-02-20 | Durch rna-interferenz vermittelte hemmung der genexpression unter verwendung von sina (short interfering nucleic acid) |
Country Status (15)
Country | Link |
---|---|
US (2) | US20090023676A1 (de) |
EP (18) | EP1432724A4 (de) |
JP (6) | JP2005524393A (de) |
AT (1) | ATE479774T1 (de) |
AU (12) | AU2003207708A1 (de) |
CA (3) | CA2476112A1 (de) |
CY (2) | CY1117168T1 (de) |
DK (4) | DK2287305T4 (de) |
ES (3) | ES2667672T3 (de) |
GB (2) | GB2396616B (de) |
HK (1) | HK1065049A1 (de) |
HU (1) | HUE036869T2 (de) |
PT (2) | PT2902406T (de) |
SI (2) | SI2902406T1 (de) |
WO (9) | WO2003072704A2 (de) |
Families Citing this family (236)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US20050171040A1 (en) * | 2001-05-18 | 2005-08-04 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of cholesteryl ester transfer protein (CEPT) gene expression using short interfering nucleic acid (siNA) |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US20050261219A1 (en) * | 2001-05-18 | 2005-11-24 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA) |
US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
DE10202419A1 (de) | 2002-01-22 | 2003-08-07 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
GB0212303D0 (en) * | 2002-05-28 | 2002-07-10 | Isis Innovation | Molecular targetting of IGF-1 receptor |
GB0212302D0 (en) * | 2002-05-28 | 2002-07-10 | Isis Innovation | Method of selecting targets for gene silencing by RNA interference |
EP1527176B2 (de) | 2002-08-05 | 2017-03-22 | Silence Therapeutics GmbH | Weitere neue formen von interferierende rns moleküle |
US8729036B2 (en) | 2002-08-07 | 2014-05-20 | University Of Massachusetts | Compositions for RNA interference and methods of use thereof |
CA2500224C (en) | 2002-09-25 | 2015-04-28 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
US9827263B2 (en) | 2002-11-05 | 2017-11-28 | Ionis Pharmaceuticals, Inc. | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
US7635770B2 (en) | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
US7592442B2 (en) | 2002-11-14 | 2009-09-22 | Dharmacon, Inc. | siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2) |
US7691998B2 (en) | 2002-11-14 | 2010-04-06 | Dharmacon, Inc. | siRNA targeting nucleoporin 62kDa (Nup62) |
US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US7655785B1 (en) | 2002-11-14 | 2010-02-02 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
US8163896B1 (en) | 2002-11-14 | 2012-04-24 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US8198427B1 (en) | 2002-11-14 | 2012-06-12 | Dharmacon, Inc. | SiRNA targeting catenin, beta-1 (CTNNB1) |
US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
EP1560931B1 (de) | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Funktionelle und hyperfunktionelle sirna |
US7951935B2 (en) | 2002-11-14 | 2011-05-31 | Dharmacon, Inc. | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US7977471B2 (en) | 2002-11-14 | 2011-07-12 | Dharmacon, Inc. | siRNA targeting TNFα |
US7619081B2 (en) | 2002-11-14 | 2009-11-17 | Dharmacon, Inc. | siRNA targeting coatomer protein complex, subunit beta 2 (COPB2) |
US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
US7612196B2 (en) | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
US7217807B2 (en) | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
WO2004063331A2 (en) * | 2003-01-03 | 2004-07-29 | Gencia Corporation | SiRNA MEDIATED POST-TRANSRIPTIONAL GENE SILENCING OF GENES INVOLVED IN ALOPECIA |
JP2006517793A (ja) * | 2003-01-31 | 2006-08-03 | ノバルティス アクチエンゲゼルシャフト | スクリーニングアッセイ |
EP2239329A1 (de) | 2003-03-07 | 2010-10-13 | Alnylam Pharmaceuticals, Inc. | Therapeutische Zusammensetzungen |
ES2576677T3 (es) | 2003-03-21 | 2016-07-08 | Roche Innovation Center Copenhagen A/S | Análogos de ARN interfirientes cortos |
CA2488224A1 (en) * | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals, Inc. | Irna conjugates |
CN101090729B (zh) | 2003-05-30 | 2014-07-23 | 艾更斯司股份有限公司 | 前列腺干细胞抗原(psca)变体及其序列 |
US7541442B2 (en) | 2003-05-30 | 2009-06-02 | Agensys, Inc. | Antibodies and related molecules that bind to PSCA proteins |
US7595379B2 (en) | 2003-05-30 | 2009-09-29 | Agensys, Inc. | Antibodies and related molecules that bind to PSCA proteins |
US7888497B2 (en) | 2003-08-13 | 2011-02-15 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
US7294704B2 (en) | 2003-08-15 | 2007-11-13 | Diadexus, Inc. | Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk |
EP1660657A1 (de) | 2003-08-28 | 2006-05-31 | Novartis AG | Interferenz-rna-duplex mit stumpfen enden und 3'-modifikationen |
EP1675949A2 (de) * | 2003-10-23 | 2006-07-05 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte hemmung der nogo- und nogo-rezeptor-genexpression unter verwendung von sina (short interfering nucleic acid) |
US7476729B2 (en) | 2003-10-24 | 2009-01-13 | Institut Curie | Dbait and uses thereof |
EP1526177A1 (de) | 2003-10-24 | 2005-04-27 | Institut Curie | Nukleinsäuren zur Beeinflussung der Tumorzell Sterblichkeit |
US20050191653A1 (en) * | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
WO2005047504A1 (en) * | 2003-11-07 | 2005-05-26 | The Board Of Trustees Of The University Of Illinois | Induction of cellular senescence by cdk4 disruption for tumor suppression and regression |
SE0303397D0 (sv) * | 2003-12-17 | 2003-12-17 | Index Pharmaceuticals Ab | Compounds and method for RNA interference |
JP4755113B2 (ja) | 2004-01-30 | 2011-08-24 | クアーク・ファーマスーティカルス、インコーポレイテッド | 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法 |
WO2005078094A2 (en) * | 2004-02-06 | 2005-08-25 | Dharmacon, Inc. | Stabilized rnas as transfection controls and silencing reagents |
EP1713915B1 (de) | 2004-02-10 | 2009-12-16 | Sirna Therapeutics, Inc. | RNA-INTERFERENZ-VERMITTELTE HEMMUNG DER GENEXPRESSION UNTER VERWENDUNG MULTIFUNKTIONELLER siNA (SHORT INTERFERING NUCLEIC ACID) |
AU2005222902B2 (en) * | 2004-03-12 | 2010-06-10 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
JPWO2005087269A1 (ja) * | 2004-03-16 | 2008-01-24 | 株式会社ディナベック研究所 | 腫瘍増殖を抑制する方法 |
CN1977044A (zh) * | 2004-03-24 | 2007-06-06 | 肿瘤疗法科学股份有限公司 | 治疗胰腺癌的组合物和方法 |
EP2481802B1 (de) * | 2004-04-09 | 2015-06-10 | Genecare Research Institute Co., Ltd | Krebszellenspezifische Apoptoseinduktoren, die auf mit Chromosomenstabilisierung in Zusammenhang stehende Gene abzielen |
AU2005238034A1 (en) | 2004-04-23 | 2005-11-10 | The Trustees Of Columbia University In The City Of New York | Inhibition of hairless protein mRNA |
DE112004002914A5 (de) * | 2004-05-06 | 2007-05-24 | Medizinische Hochschule Hannover | Verbindungen und Verfahren zur Immunsuppression |
US7605250B2 (en) | 2004-05-12 | 2009-10-20 | Dharmacon, Inc. | siRNA targeting cAMP-specific phosphodiesterase 4D |
CA2566519C (en) | 2004-05-14 | 2020-04-21 | Rosetta Genomics Ltd. | Micrornas and uses thereof |
US7687616B1 (en) | 2004-05-14 | 2010-03-30 | Rosetta Genomics Ltd | Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof |
DE102004025881A1 (de) | 2004-05-19 | 2006-01-05 | Beiersdorf Ag | Oligoribonukleotide zur Beeinflussung des Haarwachstums |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US7795419B2 (en) | 2004-05-26 | 2010-09-14 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
US7741299B2 (en) | 2004-08-16 | 2010-06-22 | Quark Pharmaceuticals, Inc. | Therapeutic uses of inhibitors of RTP801 |
JP5766900B2 (ja) | 2004-08-23 | 2015-08-19 | シレンティス・エセ・ア・ウ | 眼内圧の上昇によって特徴付けられる眼の疾患のsiRNAによる治療 |
EP2287301A3 (de) | 2004-08-31 | 2011-11-02 | Sylentis S.A.U. | Verfahren und Zusammensetzungen zur Hemmung der P2X7-Rezeptorexpression |
BRPI0516177B8 (pt) | 2004-09-28 | 2021-05-25 | Quark Biotech Inc | oligorribonucleotídeos, uso dos mesmos, uso de um composto sirna eficaz para inibir 0 p53 humano e composição farmacêutica que os contém, bem como método para diminuição da expressão do gene p53 |
WO2006039806A1 (en) * | 2004-10-14 | 2006-04-20 | Institut De Cardiologie De Montreal | Depression of herg k+ channel function in mammalian cells and applications to the control of cancer cells division |
US20060253100A1 (en) | 2004-10-22 | 2006-11-09 | Medtronic, Inc. | Systems and Methods to Treat Pain Locally |
US7595159B2 (en) | 2004-11-03 | 2009-09-29 | The Brigham And Women's Hospital, Inc. | Prediction of Parkinson's disease using gene expression levels of peripheral blood samples |
KR100780548B1 (ko) * | 2004-12-08 | 2007-11-29 | 한국원자력연구원 | S-아데노실 메티오닌 디카르복실라제 mRNA에특이적인 작은 간섭 RNA 및 그를 유효성분으로포함하는 악성종양 치료제 |
EP1819365B1 (de) * | 2004-12-09 | 2014-07-02 | Alnylam Pharmaceuticals Inc. | Zusammensetzungen und Verfahren zur Induzierung einer Immunantwort bei einem Säugetier und Verfahren zur Vermeidung einer Immunantwort zu Oligonucleotidwirkstoffen wie etwa short interfering RNAs |
AU2011203218B2 (en) * | 2004-12-09 | 2013-02-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs |
JP2008525029A (ja) * | 2004-12-22 | 2008-07-17 | ニュークレオニクス・インコーポレイテッド | 遺伝子サイレンシングに有用なhbvおよびhcv保存配列 |
CN101287497B (zh) | 2004-12-27 | 2013-03-06 | 赛伦斯治疗公司 | 涂层脂质复合体和它们的用途 |
US8227591B2 (en) * | 2005-03-02 | 2012-07-24 | National Institute Of Immunology | Nucleotide sequences |
GB0505081D0 (en) | 2005-03-14 | 2005-04-20 | Genomica Sau | Downregulation of interleukin-12 expression by means of rnai technology |
WO2006112239A1 (ja) | 2005-04-15 | 2006-10-26 | National University Corporation Tottori University | hTERT発現調節遺伝子 |
KR20060119412A (ko) * | 2005-05-20 | 2006-11-24 | 아주대학교산학협력단 | IL-6 발현 억제를 위한 siRNA 및 이를 함유하는조성물 |
US20110125075A1 (en) * | 2005-07-15 | 2011-05-26 | National University Corporation Nagoya University | Method for control of electroporation apparatus |
US7919583B2 (en) | 2005-08-08 | 2011-04-05 | Discovery Genomics, Inc. | Integration-site directed vector systems |
MX2008002369A (es) * | 2005-08-17 | 2008-03-18 | Sirna Therapeutics Inc | Moleculas cortas de acidos nucleicos de interferencia quimicamente modificadas que actuan de mediadoras de la interferencia del acido ribonucleico. |
GB0521351D0 (en) | 2005-10-20 | 2005-11-30 | Genomica Sau | Modulation of TRPV expression levels |
GB0521716D0 (en) | 2005-10-25 | 2005-11-30 | Genomica Sau | Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases |
WO2007053803A2 (en) * | 2005-10-31 | 2007-05-10 | Centocor, Inc. | Antagonist of teb4 and methods of use |
WO2007051303A1 (en) | 2005-11-02 | 2007-05-10 | Protiva Biotherapeutics, Inc. | MODIFIED siRNA MOLECULES AND USES THEREOF |
KR20080082655A (ko) * | 2005-12-29 | 2008-09-11 | 알콘 리서치, 리미티드 | 안구의 혈관신생 치료용 IGF1R의 RNAⅰ-매개 억제 |
DOP2007000015A (es) | 2006-01-20 | 2007-08-31 | Quark Biotech Inc | Usos terapéuticos de inhibidores de rtp801 |
US7825099B2 (en) | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
US7910566B2 (en) | 2006-03-09 | 2011-03-22 | Quark Pharmaceuticals Inc. | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA |
GB0605337D0 (en) | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
ES2556128T3 (es) | 2006-03-23 | 2016-01-13 | Roche Innovation Center Copenhagen A/S | ARN interfiriente pequeño internamente segmentado |
US20100004320A1 (en) * | 2006-04-03 | 2010-01-07 | Santaris Pharma A/S | Pharmaceutical Composition |
GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
JP5466402B2 (ja) | 2006-06-08 | 2014-04-09 | 株式会社アミノアップ化学 | iNOSの発現制御作用を有するセンスオリゴヌクレオチド及びそれを含む組成物 |
CN103320508A (zh) | 2006-06-08 | 2013-09-25 | 阿明诺化学株式会社 | 基因产物的筛选方法 |
US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
EP2026843A4 (de) | 2006-06-09 | 2011-06-22 | Quark Pharmaceuticals Inc | Therapeutische verwendungen von rtp801l |
EP2423332A1 (de) | 2006-08-25 | 2012-02-29 | Oncotherapy Science, Inc. | Prognosemarker und therapeutische Targets für Lungenkrebs |
JP2010502210A (ja) * | 2006-09-07 | 2010-01-28 | ウニベルシダド・デ・サラマンカ | 遺伝子マーカーを使用する癌幹細胞の同定 |
JP5876637B2 (ja) * | 2006-10-18 | 2016-03-02 | マリーナ バイオテック,インコーポレイテッド | ニックまたはギャップの入った核酸分子およびそれらの使用 |
JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のsiRNAおよびその使用方法 |
WO2008072777A2 (en) | 2006-12-13 | 2008-06-19 | Oncotherapy Science, Inc. | Ttk as tumor marker and therapeutic target for lung cancer |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
EP2137205A2 (de) | 2007-02-26 | 2009-12-30 | Quark Pharmaceuticals, Inc. | Inhibitoren von rtp801 und ihre verwendung bei der behandlung von krankheiten |
WO2008109359A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting pdgfr family gene expression and uses thereof |
WO2008109492A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting igf1r gene expression and uses thereof |
WO2008109378A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting pdgfr gene expression and uses thereof |
WO2008109454A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting fos gene expression and uses thereof |
US7812002B2 (en) | 2007-03-21 | 2010-10-12 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer |
EP2136788B1 (de) | 2007-03-30 | 2011-10-26 | Bind Biosciences, Inc. | Krebszellen-targeting mit nanopartikeln |
US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
JP5296328B2 (ja) | 2007-05-09 | 2013-09-25 | 独立行政法人理化学研究所 | 1本鎖環状rnaおよびその製造方法 |
ES2474176T3 (es) | 2007-06-27 | 2014-07-08 | Quark Pharmaceuticals, Inc. | Composiciones y métodos para inhibir la expresión de genes pro-apopt�ticos |
US8435510B2 (en) | 2007-08-08 | 2013-05-07 | Sutter West Bay Hospitals | Platelet derived growth factor receptor supports cytomegalovirus infectivity |
EP2187900B1 (de) * | 2007-08-16 | 2016-11-09 | The Schepens Eye Research Institute, Inc. | Therapeutische zusammensetzungen zur behandlung von entzündungen von okular- und adnexgeweben |
RU2010111116A (ru) | 2007-08-24 | 2011-09-27 | Онкотерапи Сайенс, Инк. (Jp) | Pkib и naaladl2 в качестве генов-мишеней в терапии и диагностике рака предстательной железы |
RU2010111135A (ru) | 2007-08-24 | 2011-10-27 | Онкотерапи Сайенс, Инк. (Jp) | Связанные со злокачественными опухолями гены cdca5. epha7. stk31 и wdhd1 |
DK2548962T3 (en) | 2007-09-19 | 2016-04-11 | Applied Biosystems Llc | Sirna sequence-independent modification formats to reduce off-target phenotype effects in RNAI and stabilized forms thereof |
RU2487716C2 (ru) | 2007-10-03 | 2013-07-20 | Кварк Фармасьютикалс, Инк. | Новые структуры малых интерферирующих рнк (sirna) |
US20100317714A1 (en) * | 2007-11-29 | 2010-12-16 | Suzhou Ribo Life Science Co., Ltd | Complex molecule interfering the expression of target genes and its preparing methods |
AU2008342535B2 (en) | 2007-12-27 | 2015-02-05 | Arbutus Biopharma Corporation | Silencing of polo-like kinase expression using interfering RNA |
CA3069576A1 (en) * | 2008-01-09 | 2009-07-16 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of ocular inflammatory disorders |
CA2740028A1 (en) | 2008-01-23 | 2009-07-30 | Herlev Hospital | Ykl-40 as a general marker for non-specific disease |
US9040492B2 (en) * | 2008-03-31 | 2015-05-26 | National Institute Of Advanced Industrial Science And Technology | Double-stranded lipid-modified RNA having high RNA interference effect |
AU2009236219B8 (en) | 2008-04-15 | 2015-06-25 | Arbutus Biopharma Corporation | Silencing of CSN5 gene expression using interfering RNA |
EP2285385A4 (de) | 2008-04-15 | 2013-01-16 | Quark Pharmaceuticals Inc | siRNA-VERBINDUNGEN ZUR NRF2-HEMMUNG |
CN102119217B (zh) | 2008-04-15 | 2015-06-03 | 普洛体维生物治疗公司 | 用于核酸递送的新型制剂 |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
WO2009131733A1 (en) * | 2008-04-21 | 2009-10-29 | The Trustees Of Columbia University In The City Of New York | Gab2 amplification in melanoma |
US8431692B2 (en) | 2008-06-06 | 2013-04-30 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
US8309791B2 (en) | 2008-07-16 | 2012-11-13 | Recombinectics, Inc. | Method for producing a transgenic pig using a hyper-methylated transposon |
EP2329044B1 (de) | 2008-08-27 | 2016-05-18 | Oncotherapy Science, Inc. | Prmt1 für zielgene zur krebstherapie und -diagnose |
US8580520B2 (en) | 2008-09-15 | 2013-11-12 | Herlev Hospital | YKL-40 as a marker for gastrointestinal cancers |
JP2011251912A (ja) * | 2008-09-22 | 2011-12-15 | Gifu Prefecture Kenkyu Kaihatsu Zaidan | マイクロrna―143誘導体を含有する医薬 |
US20100239632A1 (en) | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
EP2432499A2 (de) | 2009-05-20 | 2012-03-28 | Schering Corporation | Modulation von pilr-rezeptoren zur behandlung mikrobieller infektionen |
CN102612560B (zh) * | 2009-06-16 | 2017-10-17 | 库尔纳公司 | 通过抑制针对对氧磷酶1(pon1)的天然反义转录物来治疗pon1相关的疾病 |
CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
US8716464B2 (en) | 2009-07-20 | 2014-05-06 | Thomas W. Geisbert | Compositions and methods for silencing Ebola virus gene expression |
US20120263709A1 (en) | 2009-09-10 | 2012-10-18 | Schering Corporation | Use of il-33 antagonists to treat fibrotic diseases |
EP2480668A2 (de) | 2009-09-23 | 2012-08-01 | Protiva Biotherapeutics Inc. | Zusammensetzungen und verfahren zur ausschaltung von in krebs exprimierten genen |
AU2010324658A1 (en) | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
WO2011084357A1 (en) | 2009-12-17 | 2011-07-14 | Schering Corporation | Modulation of pilr to treat immune disorders |
WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
CN101787366B (zh) * | 2010-03-04 | 2012-09-19 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种特异抑制Rab27B基因表达的DNA片段及其应用 |
JP2013539456A (ja) | 2010-07-28 | 2013-10-24 | アルコン リサーチ,リミテッド | VEGFAをターゲティングするsiRNA及びinvivo治療のための方法 |
EP4079856A1 (de) | 2010-08-17 | 2022-10-26 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina) |
JP6106085B2 (ja) | 2010-08-24 | 2017-03-29 | サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. | 内部非核酸スペーサーを含む一本鎖RNAi剤 |
US20130224192A1 (en) * | 2010-09-02 | 2013-08-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for the prognosis of the progression of cancer |
EP2433644A1 (de) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Brustkrebstherapeutika |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
EP2638912A4 (de) | 2010-11-12 | 2015-01-21 | Nat Univ Corp Ehime Univ | Zusammensetzungen mit einem antisense-oligonukleotid gegen mikro-rna |
WO2012106556A2 (en) | 2011-02-02 | 2012-08-09 | Amgen Inc. | Methods and compositons relating to inhibition of igf-1r |
KR20140066671A (ko) * | 2011-06-27 | 2014-06-02 | 메디뮨 엘엘씨 | 자가면역 질환에서 사용되는 마이크로rna-31 조성물 및 방법 |
PT2726613T (pt) | 2011-06-30 | 2018-10-26 | Arrowhead Pharmaceuticals Inc | Composições e métodos para inibição da expressão de genes do vírus da hepatite b |
WO2013010045A1 (en) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Novel methods and formulations for orthopedic cell therapy |
US20140243391A1 (en) | 2011-07-22 | 2014-08-28 | Centre National De La Recherche Scientifique | Phospholipid-detergent conjugates and uses thereof |
WO2013071022A1 (en) * | 2011-11-10 | 2013-05-16 | Shire Human Genetic Therapies, Inc. | Antisense oligonucleotide modulators of serotonin receptor 2c and uses thereof |
US9700619B2 (en) | 2011-11-11 | 2017-07-11 | Duke University | Combination drug therapy for the treatment of solid tumors |
US9796974B2 (en) * | 2011-11-18 | 2017-10-24 | Alnylam Pharmaceuticals, Inc. | Modified RNAi agents |
HUE041494T2 (hu) | 2012-02-24 | 2019-05-28 | Arbutus Biopharma Corp | Trialkil-kationos lipidek és alkalmazási módszereik |
US11180760B2 (en) * | 2012-03-09 | 2021-11-23 | The Johns Hopkins University | Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders |
TWI480043B (zh) * | 2012-05-01 | 2015-04-11 | Univ Kaohsiung Medical | 用以治療塑化劑引發之雌激素受體陰性型乳癌的醫藥組成物 |
EP2844261B1 (de) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | Sina-zusammensetzungen |
WO2013177194A1 (en) * | 2012-05-22 | 2013-11-28 | University Of Massachusetts | Compositions and methods for decreasing leukocyte extravasation and vessel fluid leakage |
WO2013192233A1 (en) * | 2012-06-18 | 2013-12-27 | Isis Pharmaceuticals, Inc. | Compounds and method for improved cellular uptake of antisense compounds |
US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
WO2014018375A1 (en) | 2012-07-23 | 2014-01-30 | Xenon Pharmaceuticals Inc. | Cyp8b1 and uses thereof in therapeutic and diagnostic methods |
EP2700949A1 (de) | 2012-08-24 | 2014-02-26 | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. | Verwendung von Biliverdinreduktaseproteinen als Krebsmarker |
GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
WO2014037686A1 (en) | 2012-09-05 | 2014-03-13 | Sylentis S.A.U. | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions |
US9540640B2 (en) | 2012-09-06 | 2017-01-10 | Health Research, Inc. | Compositions and methods for inhibiting hypdxia induced damage |
EP2970909A4 (de) | 2013-03-15 | 2017-02-15 | The University of Chicago | Verfahren und zusammensetzungen in zusammenhang mit t-zell aktivität |
JP6461917B2 (ja) | 2013-04-20 | 2019-01-30 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | エクソン2標的U7snRNAポリヌクレオチド構築物の組換えアデノ随伴ウイルスによる送達 |
EP3003290B1 (de) * | 2013-06-05 | 2021-03-10 | AgeX Therapeutics, Inc. | Zusammensetzungen zur verwendung in der behandlung von wunden in säugerspezies |
WO2015082080A1 (en) | 2013-12-05 | 2015-06-11 | Silence Therapeutics Gmbh | Means for lung specific delivery |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
US10011837B2 (en) | 2014-03-04 | 2018-07-03 | Sylentis Sau | SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions |
PE20170024A1 (es) | 2014-05-19 | 2017-03-17 | Pfizer | Compuestos de 6,8-dioxabiciclo [3.2.1] octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr |
US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
US9790509B2 (en) | 2014-07-18 | 2017-10-17 | Oregon Health & Science University | 5′-triphosphate oligoribonucleotides |
JP6986444B2 (ja) | 2014-08-09 | 2021-12-22 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Dmd遺伝子のエクソン5内の内部リボソーム進入部位を活性化するための方法及び材料 |
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
CA2965696A1 (en) | 2014-11-12 | 2016-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Treatment of hormonal disorders of growth |
RU2563989C1 (ru) * | 2014-11-20 | 2015-09-27 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Композиция для подавления экспрессии гена цитокина интерлейкина-4 |
CA2991639A1 (en) | 2015-08-07 | 2017-02-16 | Arrowhead Pharmaceuticals, Inc. | Rnai therapy for hepatitis b virus infection |
WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
MA45470A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques kras et leurs utilisations |
MA45469A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques de bêta-caténine et leurs utilisations |
MA45349A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques egfr et leurs utilisations |
JP7177439B2 (ja) * | 2016-05-10 | 2022-11-24 | 国立大学法人 東京医科歯科大学 | 炎症促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法 |
US10036024B2 (en) | 2016-06-03 | 2018-07-31 | Purdue Research Foundation | siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD) |
EP3269732A1 (de) * | 2016-07-11 | 2018-01-17 | Rhemastem SRLS | Therapeutisches medium zur behandlung von krebs |
JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
EP3315125A1 (de) | 2016-10-31 | 2018-05-02 | Silence Therapeutics (London) Ltd | Lipidnanopartikelformulierung |
AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
US11723912B2 (en) | 2016-12-08 | 2023-08-15 | University Of Utah Research Foundation | Staufen1 agents and associated methods |
CA3049424A1 (en) | 2017-01-06 | 2018-07-12 | Avidity Biosciences Llc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
WO2018132432A1 (en) | 2017-01-10 | 2018-07-19 | Arrowhead Pharmaceuticals, Inc. | Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
CN111447922A (zh) * | 2017-04-19 | 2020-07-24 | 拜奥-帕斯控股股份有限公司 | 用于igf-1r抑制的p-乙氧基核酸 |
JP7186721B2 (ja) * | 2017-04-19 | 2022-12-09 | バイオ-パス ホールディングス, インコーポレイテッド | Igf-1r阻害のためのp-エトキシ核酸 |
CA3066959A1 (en) | 2017-06-16 | 2018-12-20 | Imba - Institut Fur Molekulare Biotechnologie Gmbh | Blood vessel organoid, methods of producing and using said organoids |
GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
AU2018364001A1 (en) * | 2017-11-09 | 2020-06-25 | National University Corporation Tokyo Medical And Dental University | Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method |
KR20240007965A (ko) | 2017-12-06 | 2024-01-17 | 어비디티 바이오사이언시스 인크. | 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법 |
CA3090305A1 (en) * | 2018-02-28 | 2019-09-06 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents |
JP2021527649A (ja) | 2018-06-14 | 2021-10-14 | ユニバーシティー オブ ユタ リサーチ ファウンデーションUniversity of Utah Research Foundation | Staufen1調節剤および関連する方法 |
CN108977445B (zh) * | 2018-06-29 | 2021-05-25 | 山东农业大学 | 拟南芥microRNA400在调控植物耐镉性中的应用 |
WO2020011653A1 (en) | 2018-07-09 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting kynu |
WO2020011743A1 (en) | 2018-07-09 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting mafb |
US10857174B2 (en) | 2018-07-27 | 2020-12-08 | United States Government As Represented By The Department Of Veterans Affairs | Morpholino oligonucleotides useful in cancer treatment |
EP3833397A4 (de) * | 2018-08-08 | 2023-06-14 | Arcturus Therapeutics, Inc. | Zusammensetzungen und mittel gegen nicht-alkoholische steatohepatitis |
US11492623B2 (en) | 2018-08-13 | 2022-11-08 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof |
KR102097794B1 (ko) * | 2018-09-17 | 2020-04-06 | 차의과학대학교 산학협력단 | 신규한 miRNA smR-167 및 폐암 예방 또는 치료를 위한 이의 용도 |
KR102630499B1 (ko) | 2018-12-21 | 2024-01-30 | 어비디티 바이오사이언시스 인크. | 항트랜스페린 수용체 항체 및 이의 용도 |
WO2020225779A1 (en) | 2019-05-09 | 2020-11-12 | Istituto Pasteur Italia - Fondazione Cenci Bolognetti | Rig-i agonists for cancer treatment and immunotherapy |
EP4121063A4 (de) | 2020-03-19 | 2024-07-03 | Avidity Biosciences Inc | Zusammensetzungen und verfahren zur behandlung von fazioskapulohumeraler muskeldystrophie |
KR20220161378A (ko) | 2020-03-27 | 2022-12-06 | 어비디티 바이오사이언시스 인크. | 근이영양증의 치료용 조성물 및 방법 |
WO2023043953A1 (en) | 2021-09-16 | 2023-03-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
WO2023144798A1 (en) | 2022-01-31 | 2023-08-03 | Genevant Sciences Gmbh | Ionizable cationic lipids for lipid nanoparticles |
WO2023144792A1 (en) | 2022-01-31 | 2023-08-03 | Genevant Sciences Gmbh | Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU630076B2 (en) | 1987-09-21 | 1992-10-22 | Gen-Probe Incorporated | Non-nucleotide linking reagents for nucleotide probes |
WO1990014090A1 (en) * | 1989-05-19 | 1990-11-29 | Hem Research, Inc. | SHORT THERAPEUTIC dsRNA OF DEFINED STRUCTURE |
WO1991003162A1 (en) | 1989-08-31 | 1991-03-21 | City Of Hope | Chimeric dna-rna catalytic sequences |
US5962219A (en) | 1990-06-11 | 1999-10-05 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-selex |
CA2093664C (en) | 1990-10-12 | 2003-07-29 | Fritz Eckstein | Modified ribozymes |
DE4216134A1 (de) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
ATE515510T1 (de) * | 1991-12-24 | 2011-07-15 | Isis Pharmaceuticals Inc | Durch dna-abschnitte unterbrochene modifizierte oligonukleotide |
US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
CA2135646A1 (en) | 1992-05-11 | 1993-11-25 | Kenneth G. Draper | Method and reagent for inhibiting viral replication |
US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
US5804683A (en) | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
US20030125270A1 (en) | 2000-12-18 | 2003-07-03 | Lawrence Blatt | Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection |
US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
NZ255028A (en) * | 1992-07-02 | 1997-03-24 | Hybridon Inc | Antisense oligonucleotides resistant to nucleolytic degradation |
JPH07509133A (ja) | 1992-07-17 | 1995-10-12 | リボザイム・ファーマシューティカルズ・インコーポレイテッド | 動物疾患の処置のための方法および剤 |
US6174868B1 (en) * | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US5985558A (en) * | 1997-04-14 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos |
WO1994016736A1 (en) | 1993-01-22 | 1994-08-04 | University Research Corporation | Localization of therapeutic agents |
DE69433520T2 (de) * | 1993-07-10 | 2004-11-11 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | Antisense-nukleinsäure enthaltende pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zelltod, und zur behandlung von neoplasmen |
US5731294A (en) * | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
US6410322B1 (en) * | 1993-07-27 | 2002-06-25 | Hybridon Inc | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
EP0748382B1 (de) | 1993-09-02 | 2002-11-06 | Ribozyme Pharmaceuticals, Inc. | Enzymatische nukleiksaüre die nicht-nukleotide enthaltet |
US5990090A (en) * | 1993-09-20 | 1999-11-23 | The University Of Michigan | Methods and compositions for treatment of diseases |
US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
ATE174600T1 (de) | 1993-10-27 | 1999-01-15 | Ribozyme Pharm Inc | 2'-amido-und 2'-peptido-modifizierte oligonukleotide |
WO1995022600A1 (en) * | 1994-02-22 | 1995-08-24 | Immusol, Inc. | Ribozyme therapy for hepatitis b infection |
US5902880A (en) | 1994-08-19 | 1999-05-11 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
US6146886A (en) | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5716824A (en) | 1995-04-20 | 1998-02-10 | Ribozyme Pharmaceuticals, Inc. | 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes) |
WO1996018736A2 (en) | 1994-12-13 | 1996-06-20 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses |
US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
WO2002096927A2 (en) * | 2001-05-29 | 2002-12-05 | Ribozyme Pharmaceuticals, Incorporated | Ribozyme based treatment of female reproductive diseases |
DE69619132T2 (de) * | 1995-11-14 | 2002-07-18 | Vimrx Holdings Ltd | Chimäre oligomere mit einer rns-spaltungsaktivität |
US5998203A (en) * | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
EP0886641A2 (de) | 1996-01-16 | 1998-12-30 | Ribozyme Pharmaceuticals, Inc. | Synthese von methoxynukleoside und enzymatische nukleinsäure moleküle |
US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
US6248878B1 (en) | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
US6001311A (en) | 1997-02-05 | 1999-12-14 | Protogene Laboratories, Inc. | Apparatus for diverse chemical synthesis using two-dimensional array |
EP0972019A1 (de) * | 1997-03-28 | 2000-01-19 | The Research Foundation Of State University Of New York | Antisense oligonukleotide für mitogen-antivierten protein-kinasen zur brustkrebs therapie |
US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
CA2301166A1 (en) * | 1997-07-24 | 1999-02-04 | Yuan-Peng Zhang | Liposomal compositions for the delivery of nucleic acid catalysts |
AR013269A1 (es) | 1997-08-04 | 2000-12-13 | Scras | Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral |
JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ/エス | オリゴヌクレオチド類似体 |
EP1019065A4 (de) * | 1997-09-17 | 2002-02-20 | Univ East Carolina | Vielzahl zielgerichteter, hybridisierender nukleinsäuren, deren synthese, zusammensetzung, formulierung, kits und anwendung |
US6054576A (en) | 1997-10-02 | 2000-04-25 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA |
CA2228977A1 (en) * | 1997-11-07 | 1999-05-07 | Martin G. Sirois | Localized oligonucleotide therapy for preventing restenosis |
US5932580A (en) * | 1997-12-01 | 1999-08-03 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | PDGF receptor kinase inhibitory compounds their preparation and compositions |
EP1038016A2 (de) | 1997-12-16 | 2000-09-27 | Valentis Inc. | Nadelloses injektion von formulierte nukleinsäure moleküle |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
KR20010042069A (ko) * | 1998-03-20 | 2001-05-25 | 베니텍 오스트레일리아 리미티드 | 유전자 발현 조절방법 |
WO1999053050A1 (en) | 1998-04-08 | 1999-10-21 | Commonwealth Scientific And Industrial Research Organisation | Methods and means for obtaining modified phenotypes |
JP2003525017A (ja) | 1998-04-20 | 2003-08-26 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | 遺伝子発現を調節しうる新規な化学組成を有する核酸分子 |
GB9827152D0 (en) * | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
DE69926007T2 (de) * | 1998-10-07 | 2005-12-29 | Medical College Of Georgia Research Institute, Inc. | Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon |
DK1119371T3 (da) * | 1998-10-09 | 2011-03-07 | Vegenics Ltd | Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi |
US6069008A (en) * | 1998-11-25 | 2000-05-30 | Isis Pharmaceuticals Inc. | Antisense modulation of NF-kappa-B p65 subunit expression |
AU776150B2 (en) * | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
WO2000049035A1 (en) * | 1999-02-19 | 2000-08-24 | The General Hospital Corporation | Gene silencing |
US5998206A (en) * | 1999-02-23 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense inhibiton of human G-alpha-12 expression |
MXPA01009073A (es) | 1999-03-10 | 2002-05-06 | Phogen Ltd | Suministro de acidos nucleicos y proteinas a las celulas. |
KR20010112944A (ko) | 1999-04-21 | 2001-12-22 | 이곤 이 버그 | 폴리뉴클레오티드 서열의 기능을 억제하기 위한 방법 및조성물 |
AU776362B2 (en) | 1999-05-04 | 2004-09-09 | Roche Innovation Center Copenhagen A/S | L-ribo-LNA analogues |
AU768904B2 (en) * | 1999-06-21 | 2004-01-08 | Murdoch Childrens Research Institute, The | A method for the prophylaxis and/or treatment of medical disorders |
CA2378653A1 (en) | 1999-07-09 | 2001-01-18 | American Home Products Corporation | Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence |
US20040002153A1 (en) * | 1999-07-21 | 2004-01-01 | Monia Brett P. | Modulation of PTEN expression via oligomeric compounds |
AUPQ201499A0 (en) * | 1999-08-04 | 1999-08-26 | Unisearch Limited | Treatment of inflammatory and malignant diseases |
WO2001016346A1 (en) * | 1999-08-30 | 2001-03-08 | Wisconsin Alumni Research Foundation | Production of 3-hydroxypropionic acid in recombinant organisms |
AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
AU1767301A (en) | 1999-11-29 | 2001-06-04 | Cold Spring Harbor Laboratory | Regulation of polycomb group gene expression for increasing seed size in plants |
RU2164944C1 (ru) | 1999-12-09 | 2001-04-10 | Институт молекулярной биологии им. В.А. Энгельгардта РАН | Способ изменения генетических свойств организма |
AU2625501A (en) | 1999-12-30 | 2001-07-16 | Rutgers, The State University Of New Jersey | Compositions and methods for gene silencing |
IT1316982B1 (it) | 2000-01-17 | 2003-05-26 | Univ Roma | Isolamento e caratterizzazione di un gene per il silenziamento genicoda n.crassa e suoi usi. |
US6261840B1 (en) * | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
US6602857B1 (en) * | 2000-01-18 | 2003-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
WO2003070918A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
AU2001245793A1 (en) * | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
EP1272629A4 (de) | 2000-03-17 | 2004-12-22 | Benitec Australia Ltd | Genabschaltung |
EP2319864A3 (de) | 2000-03-22 | 2012-11-21 | Sanofi-Aventis Deutschland GmbH | Nematodes as model organisms for the investigation of neurodegenerative diseases, in particular parkinson's disease, use and method |
GB0007268D0 (en) | 2000-03-24 | 2000-05-17 | Cyclacel Ltd | Cell cycle progression proteins |
KR101215789B1 (ko) | 2000-03-30 | 2012-12-26 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Rna 간섭의 rna 서열 특이적인 매개체 |
ATE513910T1 (de) | 2000-05-30 | 2011-07-15 | Johnson & Johnson Res Pty Ltd | Methoden zur gensuppression mithilfe von rnai verstärkenden faktoren |
US20020177552A1 (en) * | 2000-06-09 | 2002-11-28 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
AU2001275474A1 (en) * | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
KR20030036238A (ko) * | 2000-06-23 | 2003-05-09 | 쉐링 악티엔게젤샤프트 | VEGF/VEGF 수용체 및 안지오포이에틴/Tie수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ) |
WO2002007747A1 (en) * | 2000-07-18 | 2002-01-31 | Joslin Diabetes Center, Inc. | Methods of modulating fibrosis |
US6613567B1 (en) * | 2000-09-15 | 2003-09-02 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Her-2 expression |
EP2322648A1 (de) * | 2000-09-26 | 2011-05-18 | Duke University | RNA-Aptamere und Verfahren zu ihrer Identifizierung |
JP2002117576A (ja) * | 2000-10-03 | 2002-04-19 | Tdk Corp | 光記録媒体および光学的情報記録方法 |
EP1390498A2 (de) * | 2000-10-26 | 2004-02-25 | Beth Israel Deaconess Medical Center, Inc. | Gab2(p97) gen und verfahren zu dessen verwendung |
DE60135482D1 (de) | 2000-11-09 | 2008-10-02 | Cenix Bioscience Gmbh | Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen |
CZ302719B6 (cs) * | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
EP1233059A1 (de) * | 2001-02-09 | 2002-08-21 | ARTEMIS Pharmaceuticals GmbH | Influenza Viren mit verstärkten Transkriptions- und Replikationsfähigkeiten |
US20030087855A1 (en) | 2001-09-13 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of protein kinase R expression |
EP1386004A4 (de) | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | Modulation der mit der entzündungsausbreitung und dem neuritenauswuchs assoziierten genexpression unter verwendung von technologien auf nukleinsäurebasis |
WO2003070910A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
US20040019001A1 (en) * | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
PT2070939E (pt) | 2001-05-25 | 2014-06-09 | Univ Duke | Moduladores de agentes farmacológicos |
US20030166282A1 (en) * | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
JP2005527198A (ja) * | 2002-02-14 | 2005-09-15 | シティ・オブ・ホープ | 哺乳動物細胞において、干渉rna分子を産生する方法、および該干渉rna分子の療法的使用 |
AUPS078002A0 (en) * | 2002-02-27 | 2002-03-21 | Unisearch Limited | Dnazyme therapeutics |
US20040121353A1 (en) * | 2002-05-23 | 2004-06-24 | Ceptyr, Inc. | Modulation of TCPTP signal transduction by RNA interference |
WO2003099298A1 (en) * | 2002-05-24 | 2003-12-04 | Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
CA2388441A1 (en) * | 2002-06-10 | 2003-12-10 | Wei-Ping Min | Immunomodulation using rna interference |
EP1527176B2 (de) | 2002-08-05 | 2017-03-22 | Silence Therapeutics GmbH | Weitere neue formen von interferierende rns moleküle |
EP1389637B1 (de) * | 2002-08-05 | 2012-05-30 | Silence Therapeutics Aktiengesellschaft | Interferierende RNS Moleküle mit glatten Enden |
CA2500224C (en) * | 2002-09-25 | 2015-04-28 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
US20040248299A1 (en) * | 2002-12-27 | 2004-12-09 | Sumedha Jayasena | RNA interference |
JP2006519594A (ja) * | 2003-02-11 | 2006-08-31 | イミューソル インコーポレイテッド | 所定のタンパク質ファミリー用に最適化したsiRNAライブラリー |
CA2528963A1 (en) * | 2003-06-27 | 2005-01-13 | Sirna Therapeutics, Inc. | Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina) |
US8240498B2 (en) | 2006-10-31 | 2012-08-14 | Crown Packaging Technology, Inc. | Resealable closure |
CN107249491A (zh) | 2015-06-01 | 2017-10-13 | 奥林巴斯株式会社 | 医疗用机械手 |
-
2003
- 2003-01-28 EP EP03705941A patent/EP1432724A4/de not_active Withdrawn
- 2003-01-28 AU AU2003207708A patent/AU2003207708A1/en not_active Abandoned
- 2003-02-05 WO PCT/US2003/003473 patent/WO2003072704A2/en not_active Application Discontinuation
- 2003-02-05 EP EP03715980A patent/EP1476458A4/de not_active Withdrawn
- 2003-02-05 AU AU2003219712A patent/AU2003219712A1/en not_active Abandoned
- 2003-02-11 JP JP2003569651A patent/JP2005524393A/ja active Pending
- 2003-02-11 CA CA002476112A patent/CA2476112A1/en not_active Abandoned
- 2003-02-11 WO PCT/US2003/004347 patent/WO2003070886A2/en not_active Application Discontinuation
- 2003-02-11 AU AU2003211082A patent/AU2003211082A1/en not_active Abandoned
- 2003-02-11 EP EP03716024A patent/EP1472267A4/de not_active Withdrawn
- 2003-02-11 AU AU2003219751A patent/AU2003219751A1/en not_active Abandoned
- 2003-02-11 WO PCT/US2003/004566 patent/WO2003070744A1/en active Application Filing
- 2003-02-11 EP EP03742769A patent/EP1472269A4/de not_active Withdrawn
- 2003-02-18 AU AU2003247204A patent/AU2003247204A1/en not_active Abandoned
- 2003-02-18 AU AU2003216311A patent/AU2003216311A1/en not_active Abandoned
- 2003-02-18 EP EP03742820A patent/EP1470256A4/de not_active Withdrawn
- 2003-02-18 WO PCT/US2003/004909 patent/WO2003070903A2/en not_active Application Discontinuation
- 2003-02-18 EP EP03742821A patent/EP1549660A4/de not_active Withdrawn
- 2003-02-18 WO PCT/US2003/004907 patent/WO2003070968A2/en not_active Application Discontinuation
- 2003-02-20 AU AU2003221258A patent/AU2003221258B2/en not_active Expired
- 2003-02-20 PT PT141956276T patent/PT2902406T/pt unknown
- 2003-02-20 DK DK10008929.1T patent/DK2287305T4/en active
- 2003-02-20 AU AU2003213163A patent/AU2003213163A1/en not_active Abandoned
- 2003-02-20 EP EP03716126A patent/EP1458741B1/de not_active Expired - Lifetime
- 2003-02-20 EP EP08075778A patent/EP2042510A3/de not_active Withdrawn
- 2003-02-20 EP EP03713549A patent/EP1476574A4/de not_active Withdrawn
- 2003-02-20 EP EP10008929.1A patent/EP2287305B2/de not_active Expired - Lifetime
- 2003-02-20 DK DK14195627.6T patent/DK2902406T3/en active
- 2003-02-20 EP EP17209752.9A patent/EP3354656B1/de not_active Expired - Lifetime
- 2003-02-20 EP EP10008931A patent/EP2278004B1/de not_active Expired - Lifetime
- 2003-02-20 JP JP2003569811A patent/JP2005517438A/ja not_active Withdrawn
- 2003-02-20 AU AU2003217594A patent/AU2003217594A1/en not_active Abandoned
- 2003-02-20 CA CA002455447A patent/CA2455447A1/en not_active Abandoned
- 2003-02-20 DK DK10008930.9T patent/DK2287306T3/da active
- 2003-02-20 WO PCT/US2003/005044 patent/WO2003070911A2/en not_active Application Discontinuation
- 2003-02-20 AU AU2003216324A patent/AU2003216324B2/en not_active Expired
- 2003-02-20 WO PCT/US2003/005162 patent/WO2003070914A2/en not_active Application Discontinuation
- 2003-02-20 EP EP14195627.6A patent/EP2902406B1/de not_active Expired - Lifetime
- 2003-02-20 ES ES14195627.6T patent/ES2667672T3/es not_active Expired - Lifetime
- 2003-02-20 ES ES10008930T patent/ES2394269T3/es not_active Expired - Lifetime
- 2003-02-20 GB GB0404912A patent/GB2396616B/en not_active Expired - Lifetime
- 2003-02-20 WO PCT/US2003/004951 patent/WO2003070970A2/en not_active Application Discontinuation
- 2003-02-20 AU AU2003216315A patent/AU2003216315A1/en not_active Abandoned
- 2003-02-20 ES ES10008929.1T patent/ES2534045T5/es not_active Expired - Lifetime
- 2003-02-20 HU HUE14195627A patent/HUE036869T2/hu unknown
- 2003-02-20 PT PT100089291T patent/PT2287305E/pt unknown
- 2003-02-20 AT AT03743684T patent/ATE479774T1/de active
- 2003-02-20 GB GB0406022A patent/GB2397818B/en not_active Expired - Lifetime
- 2003-02-20 CA CA002459532A patent/CA2459532A1/en not_active Abandoned
- 2003-02-20 EP EP03743684.7A patent/EP1423406B2/de not_active Expired - Lifetime
- 2003-02-20 EP EP21166750.6A patent/EP3926046A3/de not_active Withdrawn
- 2003-02-20 DK DK03743684.7T patent/DK1423406T3/da active
- 2003-02-20 EP EP18203871.1A patent/EP3459963A1/de not_active Withdrawn
- 2003-02-20 JP JP2003573107A patent/JP2005518803A/ja not_active Withdrawn
- 2003-02-20 SI SI200332566T patent/SI2902406T1/en unknown
- 2003-02-20 WO PCT/US2003/005028 patent/WO2003074654A2/en active Application Filing
- 2003-02-20 EP EP03742826A patent/EP1470257A4/de not_active Withdrawn
- 2003-02-20 EP EP10008930.9A patent/EP2287306B2/de not_active Expired - Lifetime
- 2003-02-20 SI SI200332420T patent/SI2287305T2/en unknown
-
2004
- 2004-10-15 HK HK04107996.5A patent/HK1065049A1/xx not_active IP Right Cessation
-
2006
- 2006-03-01 JP JP2006117199A patent/JP2006271387A/ja not_active Withdrawn
-
2008
- 2008-06-05 JP JP2008148596A patent/JP2008289488A/ja not_active Withdrawn
- 2008-08-05 JP JP2008201593A patent/JP2009060893A/ja active Pending
- 2008-08-29 US US12/201,759 patent/US20090023676A1/en not_active Abandoned
-
2010
- 2010-08-18 AU AU2010212416A patent/AU2010212416B2/en not_active Expired
-
2012
- 2012-05-15 US US13/471,857 patent/US8648185B2/en not_active Expired - Lifetime
-
2015
- 2015-04-06 CY CY20151100330T patent/CY1117168T1/el unknown
-
2018
- 2018-04-26 CY CY20181100444T patent/CY1120292T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120292T1 (el) | ΔΙΑΜΕΣΟΛΑΒΟΥΜΕΝΗ ΑΠΟ RNA ΠΑΡΕΜΒΟΛΗ ΑΝΑΣΤΟΛΗ ΤΗΣ ΓΟΝΙΔΙΑΚΗΣ ΕΚΦΡΑΣΗΣ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ΒΡΑΧΥ ΠΑΡΕΜΒΑΛΛΟΜΕΝΟ ΝΟΥΚΛΕΪΚΟ ΟΞΥ (siNA) | |
WO2003070918A3 (en) | Rna interference by modified short interfering nucleic acid | |
WO2003070887A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
WO2003070896A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
WO2003070197A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
EP1710307A3 (de) | Durch RNA-Interferenz vermittelte Hemmung der Genexpression unter Verwendung von siNA (short interfering nucleic acid) | |
WO2003070885A3 (en) | SHORT INTERFERING NUCLEIC ACID INHIBITION OF STEAROYL-CoA DESATURASE (SCD) GENE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1423406 Country of ref document: EP |